BeStock  
Stocks › GLUE

Monte Rosa Therapeutics GLUE

US equityMarket cap rank #3349
$8.64 −$0.27 (-3.03%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $8.64 0.00%
Open$8.73
Prev close$8.91
Day range$8.48 – $9.04
Volume2.52M
Market cap$738.29M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership117.9%-0.61 pts vs. prior quarter
Institutions holding232-4 vs. prior quarter
Insider trades (recent)11 buys / 36 sellsNet selling
Short interest24.45% of floatDays to cover 15.7 · as of 30 Oct 2026
Short-sale volume share16.0%5-day average of daily volume

Short-sale volume as % of daily volume

5%14%22%31%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$3.72M (3 inflow days, 17 outflow days).

Net flow by order size, last 20 sessions

−$1.7MSuper−$2.0MBig−$4.1MMid−$1.6MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 38.7% of shares outstanding.

Largest holders

  • T. Rowe Price Group, Inc.10.37%
  • BlackRock8.42%
  • New Enterprise Associates, Inc.7.83%
  • Dimension Capital Partners, LLC6.63%
  • TCG Crossover Management, LLC5.41%
  • Vestal Point Capital, LP5.38%
  • BVF Partners L.P.5.22%
  • Baker Bros. Advisors LP5.09%

By investor type

  • Mutual Fund46.83%
  • Hedge Fund42.10%
  • VC/PE Fund23.87%
  • Public Company3.45%
  • Private Company0.83%
  • Individual/Insider0.53%
  • Family Office/Trust0.36%
  • Government Pension Fund0.28%

Reported short interest has risen from 20.46% to 24.45% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Silverarc Capital Management, LLC Hedge Fund 2026/Q3 +2,004,478 3.6%
Morgan Stanley Public Company 2026/Q3 +357,635 1.3%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +357,635 1.3%
BlackRock Mutual Fund 2026/Q3 +349,359 8.4%
Y-Intercept (Hong Kong) Limited Mutual Fund 2026/Q3 +205,172 0.3%
Squarepoint OPS LLC Hedge Fund 2026/Q3 +204,627 0.3%
Dimensional Fund Advisors Mutual Fund 2026/Q3 +203,856 1.6%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +189,430 0.2%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +2,140,983 10.4%
BlackRock Mutual Fund 2026/Q3 +1,205,403 8.0%
Vestal Point Capital, LP Hedge Fund 2026/Q3 +996,535 5.4%
Woodline Partners LP Hedge Fund 2026/Q3 +888,388 1.1%
Opaleye Management Inc. Hedge Fund 2026/Q3 +745,000 0.9%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +647,796 0.8%
Boone Capital Management LLC Hedge Fund 2026/Q3 +615,287 0.7%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
4 Oct 2026 Matthew Bowen Corporate Controller & Principal Accounting Officer Open Market Disposition -13 $10.56 18,001
15 Jul 2026 Markus Warmuth Chief Executive Officer Open Market Disposition -9,500 $23.18 399,038
14 Jul 2026 Jennifer Champoux Chief Operating Officer Derivative Exercise and Sale -4,351 $23.38 4,871
5 Jul 2026 Sharon Townson Chief Scientific Officer Derivative Exercise and Sale -6,000 $24.13 5,845
30 Jun 2026 New Enterprise Associates, Inc. Other Acquisition +15,000 – 6,692,298
30 Jun 2026 New Enterprise Associates, Inc. Other Disposition -1,015,000 – 6,692,298
29 Jun 2026 Filip Janku Chief Medical Officer Derivative Exercise and Sale -5,407 $24.50 2,612
28 Jun 2026 Anthony Manning Independent Director Derivative Exercise and Sale -10,000 $23.11 –
28 Jun 2026 Filip Janku Chief Medical Officer Derivative Exercise and Sale -6,000 $22.95 1,992
23 Jun 2026 Filip Janku Chief Medical Officer Intent to Sell (Form 144) -30,000 $20.71 –
23 Jun 2026 Filip Janku Chief Medical Officer Derivative Exercise and Sale -36,000 $21.42 1,992
22 Jun 2026 Filip Janku Chief Medical Officer Automatic Disposition -5,845 $20.22 1,992
22 Jun 2026 Sharon Townson Chief Scientific Officer Derivative Exercise and Sale -3,000 $20.00 5,845
22 Jun 2026 Jennifer Champoux Chief Operating Officer Derivative Exercise and Sale -2,175 $20.00 4,871
16 Jun 2026 Sharon Townson Chief Scientific Officer Derivative Exercise and Sale -3,000 $19.00 5,845
16 Jun 2026 Jennifer Champoux Chief Operating Officer Derivative Exercise and Sale -2,176 $19.00 4,871
10 Jun 2026 Christine Siu Independent Director Other Derivative Acquisition +25,800 $17.10 25,800
10 Jun 2026 Andrew Schiff Independent Chairperson Other Derivative Acquisition +25,800 $17.10 25,800
10 Jun 2026 Anthony Manning Independent Director Other Derivative Acquisition +25,800 $17.10 25,800
10 Jun 2026 Jan Skvarka Independent Director Other Derivative Acquisition +25,800 $17.10 25,800

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 20,856,472 24.4% 15.7
15 Oct 2026 20,660,257 24.2% 11.2
30 Sep 2026 19,686,241 23.1% 18.0
15 Sep 2026 19,265,990 22.6% 17.1
31 Aug 2026 18,075,786 21.2% 16.6
14 Aug 2026 17,457,317 20.5% 14.0

Discussion

No comments yet — be the first to weigh in on GLUE.

Sign in to join the discussion.

Scroll to Top